tiprankstipranks
Advertisement
Advertisement

IBRX Stock Latest News

Unusually active option classes on open August 10th
The FlyUnusually active option classes on open August 10th
2d ago
B
COO
ImmunityBio appoints Kim as Vice Chairman
PremiumThe Fly
ImmunityBio appoints Kim as Vice Chairman
2d ago
IBRX
BTIG’s Mukherjee Reiterates Buy on ImmunityBio as ANKTIVA Growth, Upcoming QUILT-2.005 Milestones Support Unchanged $12 Price Target
PremiumRatings
BTIG’s Mukherjee Reiterates Buy on ImmunityBio as ANKTIVA Growth, Upcoming QUILT-2.005 Milestones Support Unchanged $12 Price Target
7d ago
IBRX
ImmunityBio: ANKTIVA’s Sustained Growth and Regulatory Catalysts Support Reaffirmed Buy Rating and Unchanged $15 Price Target
PremiumRatings
ImmunityBio: ANKTIVA’s Sustained Growth and Regulatory Catalysts Support Reaffirmed Buy Rating and Unchanged $15 Price Target
8d ago
IBRX
ImmunityBio reports Q2 EPS (22c) vs. (10c) last year
PremiumThe Fly
ImmunityBio reports Q2 EPS (22c) vs. (10c) last year
8d ago
IBRX
ImmunityBio wins UAE approval for ANKTIVA cancer therapies
PremiumCompany AnnouncementsImmunityBio wins UAE approval for ANKTIVA cancer therapies
13d ago
8K
IBRX
Unusually active option classes on open June 29th
Premium
The Fly
Unusually active option classes on open June 29th
1M ago
BE
WEN
Most of the Fastest Growing Companies Are Not in the S&P 500: How the Golden Eagle Dynamic Hypergrowth ETF is Built to Capture Them
Premium
Market NewsSponsored
Most of the Fastest Growing Companies Are Not in the S&P 500: How the Golden Eagle Dynamic Hypergrowth ETF is Built to Capture Them
1M ago
BE
MU
ImmunityBio Shareholders Reelect Board at 2026 Annual Meeting
PremiumCompany Announcements
ImmunityBio Shareholders Reelect Board at 2026 Annual Meeting
2M ago
8K
IBRX
ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors
PremiumCompany Announcements
ImmunityBio Advances HPV-Positive Head and Neck Cancer Trial, Setting Up a New Catalyst for IBRX Investors
2M ago
IBRX
Midday Fly By: Estee Lauder walks from Puig, Imax reportedly explores sale
PremiumThe Fly
Midday Fly By: Estee Lauder walks from Puig, Imax reportedly explores sale
3M ago
BJ
EL
ImmunityBio highlights patient survey data on NMIBC at ISPOR 2026
PremiumThe Fly
ImmunityBio highlights patient survey data on NMIBC at ISPOR 2026
3M ago
IBRX
ImmunityBio presents health economic analysis on ANKTIVA plus BCG
PremiumThe FlyImmunityBio presents health economic analysis on ANKTIVA plus BCG
3M ago
IBRX
Midday Fly By: Target, Lowe’s, TJX report Q1 beats
Premium
The Fly
Midday Fly By: Target, Lowe’s, TJX report Q1 beats
3M ago
BA
BZ
ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA
Premium
The Fly
ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA
3M ago
IBRX
ImmunityBio announces results from ITC analyses of NAI with BCG
PremiumThe Fly
ImmunityBio announces results from ITC analyses of NAI with BCG
3M ago
IBRX
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S.
PremiumCompany Announcements
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S.
3M ago
8K
IBRX
ImmunityBio announces five U.S. patents issued for Anktiva with BCG
PremiumThe Fly
ImmunityBio announces five U.S. patents issued for Anktiva with BCG
3M ago
IBRX
ImmunityBio signs exclusive U.S. agreement with Japan BCG Laboratory
PremiumThe Fly
ImmunityBio signs exclusive U.S. agreement with Japan BCG Laboratory
3M ago
IBRX
ImmunityBio price target lowered to $12 from $13 at BTIG
PremiumThe FlyImmunityBio price target lowered to $12 from $13 at BTIG
3M ago
IBRX
ImmunityBio reports Q1 EPS (62c) vs (15c) last year
Premium
The Fly
ImmunityBio reports Q1 EPS (62c) vs (15c) last year
3M ago
IBRX
ImmunityBio presents new comparison results on Anktiva, TAR-200
Premium
The Fly
ImmunityBio presents new comparison results on Anktiva, TAR-200
3M ago
IBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >